Evidence map›Paper›PMID 32316695›Full record

ArticleInternational journal of molecular sciences2020

The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis.

Kuo-Min Su, Tzu-Wei Lin, Li-Chun Liu, Yi-Pin Yang, Mong-Lien Wang, Ping-Hsing Tsai, Peng-Hui Wang, Mu-Hsien Yu, Chia-Ming Chang, Cheng-Chang Chang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Inside-Out of Complement in Cancer.Frontiers in immunology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kuo-Min SuDepartment of Obstetrics and Gynecology, Tri-service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Tzu-Wei LinDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Li-Chun LiuDepartment of Obstetrics and Gynecology, Tri-service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.ORCID 0000-0001-7022-8316
Yi-Pin YangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Mong-Lien WangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Ping-Hsing TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.ORCID 0000-0003-2141-1872
Peng-Hui WangSchool of Medicine, National Yang-Ming University, Taipei 112, Taiwan.ORCID 0000-0002-6048-8541
Mu-Hsien YuDepartment of Obstetrics and Gynecology, Tri-service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Chia-Ming ChangSchool of Medicine, National Yang-Ming University, Taipei 112, Taiwan.ORCID 0000-0001-6172-9741
Cheng-Chang ChangDepartment of Obstetrics and Gynecology, Tri-service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.ORCID 0000-0002-7356-446X
National Yang Ming Chiao Tung University · TWNational Defense Medical Center · TWTaipei Veterans General Hospital · TWTri-Service General Hospital Songshan Branch · TW

Funding

Ministry of Science and Technology MOST 107-2314-B-016-036Tri-Service General Hospital TSGH-C108-115
6 · The paper itself

Abstract

Ovarian clear cell carcinoma (OCCC) is the second most common epithelial ovarian carcinoma (EOC). It is refractory to chemotherapy with a worse prognosis after the preliminary optimal debulking operation, such that the treatment of OCCC remains a challenge. OCCC is believed to evolve from endometriosis, a chronic immune/inflammation-related disease, so that immunotherapy may be a potential alternative treatment. Here, gene set-based analysis was used to investigate the immunofunctionomes of OCCC in early and advanced stages. Quantified biological functions defined by 5917 Gene Ontology (GO) terms downloaded from the Gene Expression Omnibus (GEO) database were used. DNA microarray gene expression profiles were used to convert 85 OCCCs and 136 normal controls into to the functionome. Relevant offspring were as extracted and the immunofunctionomes were rebuilt at different stages by machine learning. Several dysregulated pathogenic functions were found to coexist in the immunopathogenesis of early and advanced OCCC, wherein the complement-activation-alternative-pathway may be the headmost dysfunctional immunological pathway in duality for carcinogenesis at all OCCC stages. Several immunological genes involved in the complement system had dual influences on patients' survival, and immunohistochemistrical analysis implied the higher expression of C3a receptor (C3aR) and C5a receptor (C5aR) levels in OCCC than in controls.

Indexed as

Adenocarcinoma, Clear CellCase-Control StudiesComplement C3aDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyHumansMachine LearningOligonucleotide Array Sequence AnalysisOvarian NeoplasmsReceptors, ComplementSurvival AnalysisComplement C3aReceptors, Complementcomplement systemgene ontology (GO)immunological functionmachine learningovarian clear cell carcinoma (OCCC)

Identifiers

PMID32316695
PMCPMC7216156
OpenAlexW3017106504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.